JAZZ - Jazz Pharmaceuticals: Undervalued Even Before GW Acquisition Kicks In
- This neurobiology specialist just completed the acquisition of GW Pharma and this bolsters their pipeline diversity and strength.
- Xywav is set up to pick up the majority of the ending Xyrem revenues and maintain the company's forward momentum.
- The fundamental question will be whether the long-term pipeline potential is being fairly valued.
- As a result of my analysis, I find the company is undervalued and catalysts will benefit investors for at least 10 years.
For further details see:
Jazz Pharmaceuticals: Undervalued Even Before GW Acquisition Kicks In